Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | SCNN1A | P37088 | 3/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 6/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2332175 | 0.94 | AR (0.48) | ARS1PR1SCNN1AADRB2ADRB1 | |
| SCHEMBL2361313 | 0.94 | AR (0.48) | ARS1PR1SCNN1AADRB2ADRB1 | |
| SCHEMBL2328950 | 0.94 | AR (0.48) | ARS1PR1SCNN1AADRB2ADRB1 | |
| Hydrochloric Acid SCHEMBL16498773 | 0.93 | AR (0.47) | ARS1PR1SCNN1AADRB2ADRB1 | |
| SCHEMBL12869175 | 0.86 | S1PR1 (0.58) | ARS1PR1ADRB2ADRB1ADRB3 | |
| SCHEMBL708870 | 0.82 | MAPK1 (0.43) | ARS1PR1SCNN1A | |
| SCHEMBL1587135 | 0.82 | AR (0.50) | ARS1PR1SCNN1AADRB2ADRB1 | |
| SCHEMBL1587139 | 0.82 | AR (0.50) | ARS1PR1SCNN1AADRB2ADRB1 | |
| SCHEMBL2328231 | 0.81 | LTA4H (0.42) | S1PR1ADRB2ADRB1ADRB3 | |
| SCHEMBL1135505 | 0.81 | LTA4H (0.54) | ARS1PR1ADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663235-B1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2013-07-24 | — | — | EP | disclosed |
| US-8431579-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431579-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20110046158-A1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046158-A1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-7868010-B2 | N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N-(4-{4-[3-(1H-tetrazol-5-yl)propoxy]phenyl}butyl)guanidine hydrochloride; absorbed less rapidly from mucosal surfaces, less reversible | PARION SCIENCES, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-7868010-B2 | N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N-(4-{4-[3-(1H-tetrazol-5-yl)propoxy]phenyl}butyl)guanidine hydrochloride; absorbed less rapidly from mucosal surfaces, less reversible | PARION SCIENCES, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-20090018144-A1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| US-20090018144-A1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| US-7410968-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2008-08-12 | — | — | US | disclosed |
| US-20080167466-A1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080167466-A1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| US-7388013-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-7388013-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-7368451-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368451-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368447-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368447-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-7247637-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-7247637-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2007-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046158-A1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | CACNA1B, CACNA1C, HCN4 | AR 3903/4885S1PR1 868/4885SCNN1A 65/4885 |
| US-20080167466-A1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | CACNA1B, CACNA1C, HCN4 | AR 3903/4885S1PR1 868/4885SCNN1A 65/4885 |
| US-20090018144-A1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | SCNN1B, SCNN1G, SCNN1A | AR 3993/4885S1PR1 954/4885SCNN1A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.